Diaceutics (LON:DXRX) Hits New 12-Month High – What’s Next?

by · The Cerbat Gem

Shares of Diaceutics PLC (LON:DXRX – Get Free Report) hit a new 52-week high during trading on Thursday . The company traded as high as GBX 176.25 and last traded at GBX 172, with a volume of 512286 shares traded. The stock had previously closed at GBX 166.

Wall Street Analyst Weigh In

Separately, Shore Capital raised their price objective on shares of Diaceutics from GBX 180 to GBX 215 and gave the stock a “buy” rating in a research note on Thursday, January 15th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of GBX 193.33.

View Our Latest Stock Report on Diaceutics

Diaceutics Trading Up 3.6%

The firm has a market capitalization of £145.56 million, a price-to-earnings ratio of -95.56 and a beta of 0.58. The business has a 50-day moving average of GBX 143.75 and a two-hundred day moving average of GBX 145.27. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 0.39.

Diaceutics Company Profile

(Get Free Report)

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.

See Also